Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell "Digital Trust" to its existing customer Tinexta InfoCert, Europe's largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo.
"Digital Trust" provides services within the digital security sector, offering IT solutions for digital identity protection and process dematerialization for healthcare organizations.
The decision to sell "Digital Trust" is part of a broader effort to streamline the Company's portfolio and reinforce its position as a focused, performance-driven organization. Cosmo is executing a clear strategic direction - prioritizing growth in AI-powered medical devices, gastrointestinal therapeutics, dermatology, and high-value CDMO services - while actively reallocating capital to the areas with the highest impact.
"Digital Trust is not a strategic asset for Cosmo, and this transaction reflects our disciplined focus on what drives the greatest impact for patients and shareholders," saidGiovanni Di Napoli, CEO of Cosmo. "This is another concrete step forward in positioning Cosmo for sustainable growth by strengthening our focus on innovation and operational excellence in our core markets."
Cosmo continues to execute its strategy to build a focused, innovation-driven healthcare company with global reach, leveraging its strong capabilities in R&D, AI integration, and commercial partnerships.
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people's lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Financial calendar
Investor Day, Zurich | July 1, 2025 |
2025 Half-Year Results and Report | July 23, 2025 |
For further information, please contact:
Cosmo Pharmaceuticals Investor Relations, investor.relations@cosmopharma.com
About Tinexta InfoCert
Tinexta Infocert, part of the Tinexta Group, is the largest Certification Authority in Europe, operating in over 20 countries. The Company provides services in digitalization, eDelivery, Digital Signature, and digital document preservation. It is an AgID-accredited operator of digital identity within the framework of SPID (Public System for the Management of Digital Identity). It aims to continue expanding internationally also through acquisitions: it holds 100% of CertEurope, the largest Certification Authority in France; 51% of Camerfirma, one of the main certification authorities in Spain; and 16.7% of Authada, an innovative German Identity Provider.
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
PDF - English
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256766
SOURCE: Cosmo Pharmaceuticals N.V.
